Other than EU approval, this company really in a holding pattern. It is really boring. I don't think it is a matter of manipulation, but dead money.
People that play biotechs move in and out. They like action Watch ALXA, ACAD, SCMP, DVAX etc.
But really when is the last time we have had a PR about a new clincial study, progress witht the cancer drugs, etc.
I hope it is as simple as the company is waiting for EU approval and a CN launch, so thaey can get milesotne payments and reinvest in themselves.
News 
Market Data 
Discover 
AI
